The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro Jose A. Morales-García, Mario de la Fuente Revenga, Sandra Alonso-Gil, María Isabel Rodríguez-Franco, Amanda Feilding, Ana Perez-Castillo & Jordi Riba Scientific Reports, 2017, 7, 5309 www.nature.com/scientificreports https://www.nature.com/articles/s41598-017-05407-9 DOI:10.1038/s41598-017-05407-9 Abstract : Banisteriopsis caapi is the basic ingredient of ayahuasca, a psychotropic plant tea used in the Amazon for ritual and medicinal purposes, and by interested individuals worldwide. Animal studies and recent clinical research suggests that B. caapi preparations show antidepressant activity, a therapeutic effect that has been linked to hippocampal neurogenesis. Here we report that harmine, tetrahydroharmine and harmaline, the [...]
Lire la suiteBibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles. Dr Christian Sueur, GRECC, mars 2019. (2e version) ARAN A., CASSUTO H., LUBOTZKY : Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasability Study (P3.318), Neurology Genetics, 2018, 90 (15). http://n.neurology.org/content/90/15_Supplement/P3.318 ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E. : Brief Report : Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasability Study, Journal of Autism and Developmental Disorders, 2018 Oct 31. Doi : 10.1007/s10803-018-3808-2 BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. : Oral Cannabidiol Use in Children With Auttism Spectrum Disorder to Treat Related Symptoms [...]
Lire la suiteEndocannabinoid-Mediated Control of Synaptic Transmission Masanobu KANO, Takako OHNO-SHOSAKU, Yuki HASHIMOTODANI, Motokazu UCHIGASHIMA, and Masahiko WATANABE Physiological Reviews, 2009, 89, 1, 309-380. https://doi.org/10.1152/physrev.00019.2008 I. Introduction 310 II. Cannabinoid Receptors 311 A. CB1 receptor 311 B. CB2 receptor 315 C. “CB3” receptor 315 D. TRPV1 receptor 317 E. GPR55 receptor 317 III. CB1 Receptor Signaling 317 A. Intracellular signaling pathways 317 B. Suppression of transmitter release 318 C. Morphological changes 318 IV. Biochemistry of Endocannabinoids 318 A. Endocannabinoids 318 B. Biosynthesis of anandamide 319 C. Biosynthesis of 2-AG 320 D. Degradation of endocannabinoids 321 E. Endocannabinoid transport 321 F. Lipid raft 322 V. Endocannabinoid-Mediated Short-Term Depression 322 A. Endocannabinoid as a retrograde messenger 322 B. eCB-STD in various brain regions 324 C. Mechanisms of ecb-std 334 VI. [...]
Lire la suiteDark Classics in chemical Neuroscience : Lysergic Acid Diethylamide (LSD), David E. Nichols, ACS Chemical Neuroscience, 2018, 9, 10, 2331-2334. doi: 10.1021/acschemneuro.8b00043. Abstract : LSD is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 g) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists insight into the mental processes in their patients. The finding of serotonin in the mammalian brain in 1953, and its structural resemblance to LSD, quickly led [...]
Lire la suiteAntidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. Rafael F. Sanchez, F. de Lima Osorio, R.G. Dos Santos, L.R. Macedo, J.P. Maia-de-Oliveira, L. Wichert-Ana, D.B. de Araujo, J. Riba, J.A. Crippa, J.E. Hallak Journal of Clinical Psychopharmacology, 2016, 36, 1, 77-81. doi: 10.1097/JCP.0000000000000436. PMID : 26650973 Abstract Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of [...]
Lire la suiteBIBLIOGRAPHIE : Ayahuasca Neurophysiologie, Pharmacologie, Thérapeutique et Chamanisme Dr Christian Sueur, GRECC, janvier 2020 22 pages 1 - Ayahuasca : généralités : 1 - 5 2 - Neurophysiologie de l’ayahuasca : 6 -8 3 - Pharmacologie de l’ayahuasca : 9 4 - Ayahuasca et Thérapeutique : 12 - 17 5 - Ayahuasca, spiritualité et Chamanisme :18 - 23
Lire la suiteCannabidiol provides viable treatment opportunity for multipleneurological pathologies of autism spectrum disorder Bin Gu Global Drugs and Therapeutics, Review article, 2017, 2, 6, 1-4 doi: 10.15761/GDT.1000134 Abstract Autism spectrum disorder (ASD)is a heterogeneous neurodevelopmental disorderaffecting over 1% of the general population. While it is well established that ASD stems from a combination of genetic and environmental factors, there are no defined mechanisms of pathogenesis, rendering curative therapy very difficult to establish. No effective therapy exists for ASD, presenting an urgent clinical need for better control of common core pathologies of ASD regardless of its etiology. Cannabidiol (CBD), a major phytocannabinoid constituent of the cannabis plant, is [...]
Lire la suiteReview article : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases Valerio Chiurchiù, Mario van der Stelt, Diego Centonzed, Mauro Maccarrone, Progress in Neurobiology, 2018, 160 , 82–100 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). A B S T R A C T Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a [...]
Lire la suiteNeuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage Lorena Barataa, Luis Arruza, Maria-José Rodríguez, Esther Aleo, Eva Vierge, Enrique Criado, Elena Sobrino, Carlos Vargas, María Ceprián, Ana Gutiérrez-Rodríguez, William Hind, José Martínez-Orgado Neuropharmacology, 2018. https://doi.org/10.1016/j.neuropharm.2018.11.020 A B S T R A C T Objective : Hypothermia, the gold standard after a hypoxic-ischemic insult, is not beneficial in all treated newborns. Cannabidiol is neuroprotective in animal models of newborn hypoxic-ischemic encephalopathy. This study compared the relative efficacies of cannabidiol and hypothermia in newborn hypoxic-ischemic piglets and assessed whether addition of cannabidiol augments hypothermic neuroprotection. Methods : One day-old HI (carotid clamp and FiO2 10% for 20min) [...]
Lire la suiteNeurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018 : Responders Versus Nonresponders Eef L. Theunissen, Nadia R.P.W. Hutten, Natasha L. Mason, Stefan W. Toennes, Kim P.C. Kuypers, and Johannes G. Ramaekers Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0047 Abstract Introduction : Synthetic cannabinoid mixtures have been easily accessible for years, leading to the belief that these products were natural and harmless, which contributed to their popularity. Nevertheless, there are many reports of users ending up in hospital due to severe side effects such as tachycardia, aggression, and psychosis. Controlled studies on the effects of synthetic cannabinoids on [...]
Lire la suite